Age-dependent vascular endothelial growth factor expression and angiogenic capability of bladder smooth muscle cells: Implications for cell-seeded technology in bladder tissue engineering

Journal of Tissue Engineering and Regenerative Medicine

Volumn 3, Issue 8, 2009, Pages 579-589

  Azzarello, Joseph ^a   Kropp, Bradley P ^a   Fung, Kar Ming ^a,b   Lin, Hsueh Kung ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Bladder smooth muscle; Cell seeding; Co culture; Tissue engineering; VEGF

Indexed keywords

CELL ENGINEERING; CYTOLOGY; MUSCLE; POLYMERASE CHAIN REACTION; TISSUE REGENERATION;

ANGIOGENESIS; BLADDER SMOOTH MUSCLE; CELL SEEDING; CO-CULTURES; ENDOTHELIAL-CELLS; SMOOTH MUSCLE CELLS; SMOOTH MUSCLES; TISSUES ENGINEERINGS; TUBE FORMATION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ENDOTHELIAL CELLS;

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLADDER MUSCLE; CAPILLARY; CELL AGING; CELL CULTURE; CELL MIGRATION; CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SMOOTH MUSCLE FIBER; TISSUE ENGINEERING;

EID: 73449145269     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.199     Document Type: Article

References (43)

1. Achen MG, Williams RA, Minekus MP, et al. 2001; Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193(2): 147-154.
2. Ades EW, Candal FJ, Swerlick RA, et al. 1992; HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99(6): 683-690.
3. Atala A. 2006; Recent developments in tissue engineering and regenerative medicine. Curr Opin Pediatr 18(2): 167-171.
4. Atala A, Bauer SB, Soker S, et al. 2006; Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367(9518): 1241-1246.
5. Auerbach R, Lewis R, Shinners B, et al. 2003; Angiogenesis assays: a critical overview. Clin Chem 49(1): 32-40.
6. Baskin LS, Howard PS, Duckett JW, et al. 1993; Bladder smooth muscle cells in culture: I. Identification and characterization. J Urol 149(1): 190-197.
7. Battegay EJ, Rupp J, Iruela-Arispe L, et al. 1994; PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors. J Cell Biol 125(4): 917-928.
8. Braam B, Verhaar MC, Blankestijn P, et al. 2007; Technology insight: innovative options for end-stage renal disease - from kidney refurbishment to artificial kidney. Nat Clin Pract Nephrol 3(10): 564-572.
9. Breuer CK, Mettler BA, Anthony T, et al. 2004; Application of tissue-engineering principles toward the development of a semilunar heart valve substitute. Tissue Eng 10(11-12): 1725-1736.
10. Cao Y, Linden P, Farnebo J, et al. 1998; Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 95(24): 14389-14394.
11. Ferrara N, Davis-Smyth T. 1997; The biology of vascular endothelial growth factor. Endocr Rev 18(1): 4-25.
12. Fiedler J, Leucht F, Waltenberger J, et al. 2005; VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem Biophys Res Commun 334: 561-568.
13. Fukumoto S, Morifuji M, Katakura Y, et al. 2005; Endostatin inhibits lymph node metastasis by a downregulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metast 22: 31-38.
14. Garcia-Martinez C, Opolon P, Trochon V, et al. 1999; Angiogenesis induced in muscle by a recombinant adenovirus expressing functional isoforms of basic fibroblast growth factor. Gene Ther 6(7): 1210-1221.
15. Garcia JG, Wang P, Schaphorst KL, et al. 2002; Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability. FASEB J 16(9): 1064-1076.
16. Guan Y, Ou L, Hu G, et al. 2008; Tissue engineering of urethra using human vascular endothelial growth factor gene-modified bladder urothelial cells. Artif Organs 32(2): 91-99.
17. Hall JA, Hoyt D, Zuver C, et al. 2006; Rapid, multiwell colorimetric assay for measuring neutrophil chemoattractant activity in bronchoalveolar lavage fluid of horses with recurrent airway obstruction. J Vet Diagn Invest 18(3): 257-263.
18. Hoeben A, Landuyt B, Highley MS, et al. 2004; Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4): 549-580.
19. Jabbarzadeh E, Starnes T, Khan YM, et al. 2008; Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach. Proc Natl Acad Sci USA 105(32): 11099-11104.
20. Jain RK. 2003; Molecular regulation of vessel maturation. Nat Med 9(6): 685-693.
21. Jeltsch M, Kaipainen A, Joukov V, et al. 1997; Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276(5317): 1423-1425.
22. Kanczler JM, Oreffo RO. 2008; Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15: 100-114.
23. Kanematsu A, Yamamoto S, Ozeki M, et al. 2004; Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 25(18): 4513-4520.
24. Kedem A, Perets A, Gamlieli-Bonshtein I, et al. 2005; Vascular endothelial growth factor-releasing scaffolds enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. Tissue Eng 11(5/6): 715-722.
25. Kirkin V, Mazitschek R, Krishnan J, et al. 2001; Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem 268(21): 5530-5540.
26. Kramer J, Aguirre-Arteta AM, Thiel C, et al. 1999; A novel isoform of the smooth muscle cell differentiation marker smoothelin. J Mol Med 77(2): 294-298.
27. Li WJ, Jiang YJ, Tuan RS. 2008; Cell-nanofiber-based cartilage tissue engineering using improved cell seeding, growth factor, and bioreactor technologies. Tissue Eng A 14(5): 639-648.
28. Lin HK, Cowan R, Moore P, et al. 2004; Characterization of neuropathic bladder smooth muscle cells in culture. J Urol 171(3): 1348-1352.
29. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. 2006; Vascular endothelial growth factor localization in the adult. Am J Pathol 168(2): 639-648.
30. Migneco F, Hollister SJ, Birla RK. 2008; Tissue-engineered heart valve prostheses: 'state of the heart'. Regen Med 3(3): 399-419.
31. Mohle R, Green D, Moore MAS, et al. 1997; Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668.
32. Muller G, Behrens J, Nussbaumer U, et al. 1987; Inhibitory action of transforming growth factor β on endothelial cells. Proc Natl Acad Sci USA 84(16): 5600-5604.
33. Narita Y, Kagami H, Matsunuma H, et al. 2008; Decellularized ureter for tissue-engineered small-caliber vascular graft. J Artif Organs 11(2): 91-99.
34. Owens GK. 1995; Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75(3): 487-517.
35. Ozawa CR, Banfi A, Glazer NL, et al. 2004; Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113(4): 516-527.
36. Radisic M, Marsano A, Maidhof R, et al. 2008; Cardiac tissue engineering using perfusion bioreactor systems. Nat Protoc 3(4): 719-738.
37. Ram-Liebig G, Ravens U, Balana B, et al. 2006; New approaches in the modulation of bladder smooth muscle cells on viable detrusor constructs. World J Urol 24(4): 429-437.
38. Skalli O, Ropraz P, Trzeciak A, et al. 1986; A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103(6, pt 2): 2787-2796.
39. Sodian R, Lemke T, Fritsche C, et al. 2002; Tissue-engineering bioreactors: a new combined cell-seeding and perfusion system for vascular tissue engineering. Tissue Eng 8(5): 863-870.
40. Takahashi H, Shibuya M. 2005; The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109: 227-241.
41. ZhangY, FrimbergerD, ChengEY, et al. 2006; Challenges in a larger bladder replacement with cell-seeded and unseeded small intestinal submucosa grafts in a subtotal cystectomy model. BJU Int 98(5): 1100-1105.
42. Zhong XS, Zheng JZ, Reed E, et al. 2004; SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 324(2): 471-480.
43. Zund G, Breuer CK, Shinoka T, et al. 1997; The in vitro construction of a tissue engineered bioprosthetic heart valve. Eur J Cardiothorac Surg 11(3): 493-497.